Acrivon Therapeutics, Inc.
ACRV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781174
In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.
Holders of 5% or more of ACRV
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Acrivon Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 21.60%8.40M shares | – | Mar 23, 20261 filing | Mar 23, 2026 | SEC |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 13G/A | 6.80%2.12M shares | – | Aug 13, 20251 filing | Aug 13, 2025 | SEC |
| Citadel Advisors LLC | 13G | 5.50%1.72M shares | +0.60 ppfrom 4.90% | May 15, 20253 filings | Nov 21, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
7 Schedule 13D and 13G filings on Acrivon Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 23, 20264:28 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 21.60%8.40M shares | – | Mar 19, 2026 | SEC |
| Nov 21, 20255:36 PM ET | Citadel Advisors LLCand 6 others | 13G | 5.50%1.72M shares | +0.60 ppfrom 4.90% | Nov 14, 2025 | SEC |
| Nov 14, 20254:07 PM ET | Citadel Advisors LLCand 6 others | 13G/A | 4.90%1.54M shares | −1.10 ppfrom 6.00%Below 5% | Sep 30, 2025 | SEC |
| Aug 13, 202511:12 AM ET | Sands Capital Life Sciences Pulse Fund II, L.P.and 2 others | 13G/A | 6.80%2.12M shares | – | Jun 30, 2025 | SEC |
| Jun 4, 20254:05 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 0.00%0 shares | −9.90 ppfrom 9.90%Below 5% | Jun 2, 2025 | SEC |
| May 15, 20255:24 PM ET | Citadel Advisors LLCand 6 others | 13G/A | 6.00%1.90M shares | – | Mar 31, 2025 | SEC |
| May 1, 20258:21 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 9.90%3.10M shares | – | Apr 29, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Acrivon Therapeutics, Inc. shares.
No Form 144 notices for Acrivon Therapeutics, Inc. are on file.